Conference Coverage
about 1 month ago
Jamie Michael, MD, discusses MRI and genomics in active surveillanceabout 2 months ago
Matthew Truesdale, MD, on IsoPSA performance with and without mpMRILatest News
Aug 21, 2026 | News
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
Aug 21, 2026
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
Aug 21, 2026
The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C
Aug 20, 2026
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
Aug 20, 2026
Advertisement
Shorts
1:27
The Expert APProach: Leveraging coding to demonstrate APP productivity and value
7 minutes ago
by
Joy Maulik, CRNP(+1 more)
0:47
Hans Arora, MD, PhD, discusses the role of APPs and nurses in surgical care
a day ago
by
Hans Arora, MD, PhD
0:25
Early diagnosis and guideline-concordant penile cancer care
2 days ago
by
Luis G. Medina, MD
0:32
IVF-related incontinence: When to reassure vs refer
3 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:36
Adjuvant pembrolizumab in RCC: Counseling patients on long-term toxicity
7 days ago
by
Elizabeth Nally, MBBS
0:46
Testosterone therapy in women: Rethinking pre- and postmenopausal categories
9 days ago
by
Jessica M. Yih, MD
0:21
IVF and voiding symptoms: Start with cycle timing
10 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:01
The UroOnc Minute: The importance of BCG maintenance in NMIBC
11 days ago
by
Adam B. Weiner, MD(+1 more)
1:04
Keith Xavier, MD, URPS, shares early experience with Altaviva for male urge incontinence
14 days ago
by
Keith Xavier, MD, URPS
1:09
Adam B. Murphy, MD, MBA, MSCI, urges thoughtful AI integration to prevent clinician burnout
15 days ago
by
Adam B. Murphy, MD, MBA, MSCI
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Scott Bauer, MD, ScM, discusses an N-of-1 trial showing heterogeneous responses to long-term tamsulosin, identifying older men who may be candidates for deprescribing.
The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.
Hans Arora, MD, PhD, discusses how communication and collaborative leadership can strengthen teamwork and performance in the operating room.
The phase 2 RadiCaL trial found that adding radium-223 to cabozantinib did not improve skeletal event-free survival in metastatic renal cell carcinoma.
The phase 3 NRG-GU005 trial found SBRT improved bowel quality of life vs MH-IMRT but did not improve urinary outcomes or disease-free survival.
Daniel S. Kellner, MD, discusses patient selection for HoLEP and strategies for surgeons interested in adoption.
The NDA submission is supported by data from the phase 3 UTOPIA trial.
Ryan K. Flannigan, MD, discusses phase 2 data showing promising efficacy with sustained-release lidocaine in men with chronic scrotal pain.
A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.
A national analysis found that 51% of focal therapy procedures for prostate cancer occurred in patients with low-, high-, or very-high-risk disease, outside current guideline-supported settings.
Advertisement
The DIRECT-AI registry has enrolled its first patient to prospectively assess how the ArteraAI Prostate Test influences treatment decisions and outcomes in routine care.
Belzutifan plus lenvatinib significantly improved progression-free survival vs cabozantinib in patients with previously treated advanced clear cell renal cell carcinoma.
Nima Almassi, MD, reviews long-term evidence for bladder preservation after systemic therapy in muscle-invasive bladder cancer.
Functional reconstructive urology emerged gradually as anatomical success proved insufficient—enabled by urodynamics, neurourology, and institutional milestones, according to Sasha Vereecken, BScN, RN.
An analysis of NHANES data found that higher intake of ultra-processed foods was associated with increased prostate cancer risk among US men.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
2
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
3
The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C
4
Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC
5